The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Tumour heterogeneity in the clinic
Open accessAbstract
Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,169
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. (2009) · Nature · doi:10.1038/nature08489 · Cited by 1,069
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
Biological Diversity in Metastatic Neoplasms: Origins and Implications
Fidler, I. J., & Hart, I. R. (1982) · Science · doi:10.1126/science.7112116 · Cited by 928
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Antonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., Leversha, M. A., Jeffrey, P. D., Desantis, D., Singer, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2245 · Cited by 836
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706
Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., Li, F., Tsang, S., Wu, K., Wu, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.025 · Cited by 667
Leary, R. J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J. D., Craig, D., O’Shaughnessy, J., Kinzler, K. W., Parmigiani, G., Vogelstein, B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004742 · Cited by 635
Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm
Hou, Y., Song, L., Zhu, P., Zhang, B., Tao, Y., Xu, X., Li, F., Wu, K., Liang, J., Shao, D., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.028 · Cited by 541
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., DeFelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., MacConaill, L. E., Hahn, W. C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 533
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Lindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2482 · Cited by 523
Chan, K. A., Jiang, P., Zheng, Y. W., Liao, G. J., Sun, H., Wong, J., Siu, S. S. N., Chan, W. C., Chan, S. L., Chan, A. T., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196014 · Cited by 488
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471
Assuring the quality of next-generation sequencing in clinical laboratory practice
Gargis, A. S., Kalman, L., Berry, M. W., Bick, D. P., Dimmock, D. P., Hambuch, T., Lu, F., Lyon, E., Voelkerding, K. V., Zehnbauer, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2403 · Cited by 461
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Clonal selection drives genetic divergence of metastatic medulloblastoma
Wu, X., Northcott, P. A., Dubuc, A., Dupuy, A. J., Shih, D. J. H., Witt, H., Croul, S., Bouffet, E., Fults, D. W., Eberhart, C. G., et al. (2012) · Nature · doi:10.1038/nature10825 · Cited by 407
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370
The Implications of Clonal Genome Evolution for Cancer Medicine
Aparicio, S., & Caldas, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204892 · Cited by 356
Janjigian, Y. Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D. P., Jäger, E., Altmannsberger, H. M., Robinson, E., Tafe, L. J., Tang, L. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds104 · Cited by 356
The Genetic Basis for Cancer Treatment Decisions
Dancey, J. E., Bedard, P. L., Onetto, N., & Hudson, T. J. (2012) · Cell · doi:10.1016/j.cell.2012.01.014 · Cited by 343
Self-citationEvaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W. F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R. L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp263 · Cited by 286
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Lee, R. J., Nolop, K. B., & Saltz, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3534 · Cited by 283
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 283
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D'Angelica, M., Viale, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 282
Schmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., & Filipits, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0089 · Cited by 262
Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., & Kato, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00782.x · Cited by 256
Thompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253
Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A. M., Mauermann, O., Izbicki, J. R., Pantel, K., & Riethdorf, S. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.188557 · Cited by 227
N-of-1 Trials in the Medical Literature: A Systematic Review
Gabler, N. B., Duan, N., Vohra, S., & Kravitz, R. L. (2011) · Medical Care · doi:10.1097/mlr.0b013e318215d90d · Cited by 226
Kalikaki, A., Koutsopoulos, A., Trypaki, M., Souglakos, J., Stathopoulos, E., Georgoulias, V, Mavroudis, D., & Voutsina, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604629 · Cited by 206
Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 192
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel-Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P., Onetto, N., Stein, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Self-citationKim, H., Yoo, S.-B., Choe, J.-Y., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C.-T., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 163
Designing Transformative Clinical Trials in the Cancer Genome Era
Sleijfer, S., Bogaerts, J., & Siu, L. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3639 · Cited by 160
Self-citationPark, S. E., Tisch, A. H., Cho, E. Y., Shim, Y. M., Kim, J., Kim, H. S., Lee, J., Park, Y. H., Ahn, J. S., Park, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94af4 · Cited by 156
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
Bozzetti, C., Negri, F., Lagrasta, C. A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.121 · Cited by 154
Personalizing Oncology: Perspectives and Prospects
Mendelsohn, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3605 · Cited by 137
Kim, M. A., Lee, H., Yang, H., Bang, Y., & Kim, W. H. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04012.x · Cited by 135
Tao, Y., Ruan, J., Yeh, S., Lu, X., Wang, Y., Zhai, W., Cai, J., Ling, S., Gong, Q., Chong, Z., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108715108 · Cited by 134
HER2gene status in primary breast cancers and matched distant metastases
Tapia, C., Savic, S., Wagner, U., Schönegg, R., Novotny, H., Grilli, B., Herzog, M., Barascud, A., Zlobec, I., Cathomas, G., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1676 · Cited by 133
Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 132
Heselmeyer‐Haddad, K., Berroa-Garcia, L., Bradley, A., Ortiz-Melendez, C., Lee, W.-J., Christensen, R., Prindiville, S. A., Calzone, K. A., Soballe, P. W., Hu, Y., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.07.012 · Cited by 118
Buttitta, F., Felicioni, L., Grammastro, M. D., Filice, G., Lorito, A. D., Malatesta, S., Viola, P., Centi, I., D’Antuono, T., Zappacosta, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1958 · Cited by 118
Mick, R., Crowley, J. J., & Carroll, R. J. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00058-1 · Cited by 116
Genome evolution during progression to breast cancer
Newburger, D. E., Kashef-Haghighi, D., Weng, Z., Salari, R., Sweeney, R. T., Brunner, A. L., Zhu, S., Guo, X., Varma, S., Troxell, M. L., et al. (2013) · Genome Research · doi:10.1101/gr.151670.112 · Cited by 113
Bai, H., Wang, Z., Wang, Y., Zhuo, M., Zhou, Q., Duan, J., Yang, L., Wu, M., An, T., Zhao, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054170 · Cited by 96
Tolmachev, V., Stone‐Elander, S., & Orlova, A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70088-7 · Cited by 95
Yoon, H. H., Shi, Q., Sukov, W. R., Lewis, M. A., Sattler, C. A., Wiktor, A. E., Wu, T., Diasio, R. B., Jenkins, R. B., & Sinicrope, F. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1890 · Cited by 92
Dienstmann, R., Serpico, D., Rodon, J. A., Saura, C., Macarulla, T. M., Élez, E., Alsina, M., Capdevila, J., Pérez-García, J. M., Sánchez-Ollé, G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0290 · Cited by 89
Tran, B., Brown, A. M. K., Bedard, P. L., Winquist, E., Goss, G. D., Hotte, S. J., Welch, S. A., Hirte, H. W., Zhang, T., Stein, L. D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27817 · Cited by 86
Self-citationJohnson, C. E., Gorringe, K. L., Thompson, E. R., Opeskin, K., Boyle, S. E., Wang, Y.-K., Hill, P., Mann, G. B., & Campbell, I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1835-1 · Cited by 78
Wilmott, J. S., Tembe, V., Howle, J. R., Sharma, R. N., Thompson, J. F., Rizos, H., Lo, R. S., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0530 · Cited by 76
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 68
Comparison and validation of genomic predictors for anticancer drug sensitivity
Papillon‐Cavanagh, S., Jay, N. D., El-Hachem, N., Olsen, C., Bontempi, G., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001442 · Cited by 65
Chang, H. J., Han, S., Oh, D., Im, S., Jeon, Y. K., Park, I. A., Han, W., Noh, D.-Y., Bang, Y., & Kim, T.-Y. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr020 · Cited by 65
Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma
Sakurada, A., Lara-Guerra, H., Liu, G., Shepherd, F. A., & Tsao, M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168be93 · Cited by 63
Hollebecque, A., Massard, C., de Baère, T., Auger, N., Lacroix, L., Koubi-Pick, V., Vielh, P. R., Lazar, V., Bahleda, R., Ngo‐Camus, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2512 · Cited by 41
Kim, H., Xu, X., Yoo, S.-B., Sun, P., Jin, Y. J., Paik, J. H., Choe, G., Jheon, S., Lee, C., & Chung, J.-H. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04356.x · Cited by 34
Johnson, C., Gorringe, K. L., Er, T., Opeskin, K., Boyle, S., Wang, Y., Hill, P., Mann, G. B., & Campbell, I. (2012) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-10-s2-a93 · Cited by 26
Bedard, P. L., Oza, A. M., Tsao, M., Leighl, N. B., Shepherd, F. A., Chen, E. X., Tannock, I. F., Krzyzanowska, M. K., Dhani, N. C., Clarke, B. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.11002 · Cited by 24
Self-citationPerez, K. J., Walsh, R. J., Brilliant, K. E., Noble, L. C., Yakirevich, E., Breese, V., Jackson, C. L., Chatterjee, D. N., Pricolo, V. E., Roth, L. A., et al. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.004 · Cited by 18
Rye, I. H., Helland, Å., Sætersdal, A. B., Naume, B., Almendro, V., Polyák, K., Børessen-Dale, A. L., & Russnes, H. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p3-05-04 · Cited by 3
Cited by
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Self-citation
Metadata
- Authors
- Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L.
- Venue
- Nature
- Published
- 2013-09-18
- Volume
- 501
- Issue
- 7467
- Pages
- 355-364
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987370132
- Cited by
- 1,211
- References
- 104
- FWCI
- 33.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.